More action needed to beat malaria for good, says UN

Ahead of World Malaria Day on Friday, UN health agency WHO is calling for renewed efforts at all levels – from global policy to community action – to accelerate progress towards elimination.

Malaria is spread by some types of mosquitoes and is mostly found in tropical countries. Symptoms – which can be mild or life-threatening – include fever, chills and headache, seizures, and difficulty breathing.

Africa continues to carry a disproportionately high share of the global malaria burden.  In 2023, approximately 94 per cent of all cases, and 95 per cent of deaths, occurred in the region. Most deaths, 76 per cent, were among children under five.

Eye on elimination

WHO recalled that during the late 1990s, world leaders adopted effective policies which led to the prevention of more than two billion cases and nearly 13 million deaths since the year 2000.

As a result, 45 countries and one territory have been certified as malaria-free, and many other countries continue along the path towards elimination. 

Of the remaining 83 malaria-endemic countries worldwide, 25 reported fewer than 10 cases in 2023.

However, WHO Director-General Tedros Adhanom Ghebreyesus said history has shown that these gains are fragile because “when we divert our attention, the disease resurges, taking its greatest toll on the most vulnerable.” (HOW ABOUT USING THIS AS A PULL-QUOTE?) 

But history also reveals what is possible, he added.  Tedros insisted that “with strong political commitment, sustained investment, multisectoral action and community engagement, malaria can be defeated.”

Net investment

WHO said years of investments in the development and deployment of new malaria vaccines, as well as tools to prevent and control the disease, are paying off.

On World Malaria Day, Mali will join 19 other African countries in introducing malaria vaccines, representing a vital step towards protecting young children from one of the deadliest diseases on the continent. It is expected that the large-scale rollout of malaria vaccines in Africa will save tens of thousands of young lives every year.

Meanwhile, the expanded use of a new generation of insecticide-treated mosquito nets is set to make further inroads against the disease. 

Progress in peril

Yet, despite significant gains, malaria remains a major public health challenge. Nearly 600,000 deaths occurred in 2023 alone, with the African region hardest hit.

In many areas, progress has been hampered by fragile health systems and rising threats such as drug and insecticide resistance, WHO said. Many at-risk groups also continue to miss out on the services needed to prevent, detect and treat malaria. 

These challenges are further compounded by climate change, conflict, poverty and displacement, while funding cuts this year could further derail progress in many endemic countries, putting millions of additional lives at risk. 

A renewed call 

World Malaria Day 2025 is being celebrated under the theme Malaria ends with us: reinvest, reimagine, reignite, and WHO is calling for stepped up political and financial commitment to protect hard-won gains to date.

To reinvest, WHO is joining partners and civil society in calling on malaria-endemic countries to increase domestic spending, particularly in primary healthcare.

The agency is also stressing the need to reignite commitment to help end malaria transmission at all levels – from communities and frontline health workers, to governments, researchers, private sector innovators and donors.  

No more blood tests, now life-saving light beam to detect malaria

A fast, needle-free malaria detection tool developed by a University of Queensland-led team could help save hundreds of thousands of lives annually.

Malaria is usually detected by a blood test, but scientists have devised a method using a device that shines a beam of harmless infrared light on a person’s ear or finger for five-to-10 seconds, it collects an infrared signature that is processed by a computer algorithm.

International team leader, Dr Maggy Lord from UQ’s School of Biological Sciences, said the technology would revolutionise how malaria is fought globally.

The malaria detection tool collects an infrared signature for a mobile phone to process./CREDIT:The University of Queensland

“Currently it’s incredibly challenging to test large groups of people, such as the population of a village or town – you have to take blood from everyone and mix it with a reagent to get a result,” Dr Lord said.

“But with this tool we can find out very quickly whether a whole village or town is suffering from, or carrying, malaria.

“The technique is chemical-free, needle-free and detects malaria through the skin using infrared-light – it’s literally just a flash on a person’s skin and it’s done.

“The device is smart-phone operated, so results are acquired in real time.”

The researchers believe the technology is the first step to eliminating malaria.

Tiger Mosquito of Asia is adaing to survive the state of Illinois’s harsh winters / CREDIT: JAMES GATHANY/CDC

“According to the World Health Organisation malaria report, in 2020 there were an estimated 241 million cases worldwide and more than 600,000 died from malaria,” Dr Lord said.

“Most of the cases are in sub-Saharan Africa, where 90 per cent of deaths are children under five years old.

“The biggest challenge in eliminating the disease is the presence of asymptomatic people in a population who act as a reservoir for transmission by mosquitos.

“The World Health Organisation has proposed large-scale surveillance in endemic areas and this non-invasive, affordable and rapid tool offers a way to achieve that.”

The technology could also help tackle other diseases.

“We’ve successfully used this technology on mosquitoes to non-invasively detect infections such as malaria, Zika and dengue,” Dr Lord said.

“In our post-COVID world, it could be used to better tackle diseases as people move around the globe.

“We hope the tool could be used at ports of entry to screen travellers, minimising the re-introduction of diseases and reducing global outbreaks.

“It’s still early days, but this proof-of-concept is exciting.”

UQ collaborated with the Instituto Oswaldo Cruz, Brazil, led by Dr Rafael Maciel de Freitas, who applied the tool to detect malaria in patients in the Amazon region.

The work was funded by Fiocruz INOVA Ideias Inovadoras, Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico, Fundação Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro and by Advance Queensland Industry Research Fellowship and the National Health and Medical Research Council.

Also Read:

New ecology tools predict disease transmission among wildlife, humans

Japan, India scientists develop new approach to lessen severity of malaria

Scent, sweat from human skin attract disease-spreading mosquitoes

New ecology tools predict disease transmission among wildlife, humans

The rate that emerging wildlife diseases infect humans has steadily increased over the last three decades. Viruses, such as the global coronavirus pandemic and recent monkeypox outbreak, have heightened the urgent need for disease ecology tools to forecast when and where disease outbreaks are likely.

A University of South Florida assistant professor helped develop a methodology that will do just that – predict disease transmission from wildlife to humans, from one wildlife species to another and determine who is at risk of infection.

The methodology is a machine-learning approach that identifies the influence of variables, such as location and climate, on known pathogens. Using only small amounts of information, the system is able to identify community hot spots at risk of infection on both global and local scales.

coronavirus

“Our main goal is to develop this tool for preventive measures,” said co-principal investigator Diego Santiago-Alarcon, a USF assistant professor of integrative biology. “It’s difficult to have an all-purpose methodology that can be used to predict infections across all the diverse parasite systems, but with this research, we contribute to achieving that goal.”

With help from researchers at the Universiad Veracruzana and Instituto de Ecologia, located in Mexico, Santiago-Alarcon examined three host-pathogen systems – avian malaria, birds with West Nile virus and bats with coronavirus – to test the reliability and accuracy of the models generated by the methodology.

The team found that for the three systems, the species most frequently infected was not necessarily the most susceptible to the disease. To better pinpoint hosts with higher risk of infection, it was important to identify relevant factors, such as climate and evolutionary relationships.

By integrating geographic, environmental and evolutionary development variables, the researchers identified host species that have previously not been recorded as infected by the parasite under study, providing a way to identify susceptible species and eventually mitigate pathogen risk.

“We feel confident that the methodology is successful, and it can be applied widely to many host-pathogen systems,” Santiago-Alarcon said. “We now enter into a phase of improvement and refinement.”

The results, published in the Proceedings of the National Academy of Sciences, prove the methodology is able to provide reliable global predictions for the studied host–pathogen systems, even when using a small amount of information. This new approach will help direct infectious disease surveillance and field efforts, providing a cost-effective strategy to better determine where to invest limited disease resources.

Bats/wikipedia

Predicting what kind of pathogen will produce the next medical or veterinary infection is challenging, but necessary. As the rate of human impact on natural environments increases, opportunity for novel diseases will continue to rise.

“Humanity, and indeed biodiversity in general, are experiencing more and more infectious disease challenges as a result of our incursion and destruction of the natural order worldwide through things like deforestation, global trade and climate change,” said Andrés Lira-Noriega, research fellow at the Instituto de Ecologia. “This imposes the need of having tools like the one we are publishing to help us predict where new threats in terms of new pathogens and their reservoirs may occur or arise.”

The team plans to continue their research to further test the methodology on additional host-pathogen systems and extend the study of disease transmission to predict future outbreaks. The goal is to make the tool easily accessible through an app for the scientific community by the end of 2022.

New malaria analysis method reveals disease severity in minutes

Left untreated, malaria can progress from being mild to severe — and potentially fatal — in 24 hours. So researchers at the University of British Columbia developed a method to quickly and sensitively assess the progression of the mosquito-borne infectious disease, which remains a leading killer in low-income countries.

One way malaria wreaks havoc on the body is by causing excessive amounts of toxic heme, the non-protein component of hemoglobin, to accumulate in the bloodstream. Among other things, this free heme induces oxidative stress in red blood cells (RBCs), leading to their rigidification, destruction and subsequent removal from circulation — a condition known as hemolytic anemia.

In their study, which appeared in Integrative Biology, the UBC investigators found that RBCs become increasingly rigid in direct correlation with the concentration of oxidized heme, or hemin, in the blood. Since hemin is difficult to measure directly — it tends to insert itself into cell membranes — monitoring changes in RBC deformability can therefore serve as a reliable alternative marker of hemin-induced oxidative stress and malaria progression.

“Because this method is mechanical, it’s well suited for use in resource-poor countries, where the vast majority of malaria transmission takes place,” says Kerryn Matthews, a postdoctoral fellow at UBC and the study’s lead author. “Other methods of analyzing malaria severity require training or expensive equipment or chemicals that are not readily available in developing nations.”

To measure RBC deformability quickly and sensitively, the UBC investigators developed the “multiplex fluidic plunger”: a simple microfluidic device consisting of a parallel array of 34 funnel-shaped, micro-sized channels across which uniform, carefully controlled pressures can be simultaneously applied.

By loading the plunger with whole blood, docking an RBC at each channel and applying progressively higher pressures until the RBCs are squeezed through — or not, if an RBC is too stiff — one is able to determine the rigidity, or cortical tensions, of many cells at once and build an RBC deformability profile in minutes.

“The device can be easily integrated with a conventional microscope coupled with a digital camera,” says Matthews. “And the accompanying software, which does all the analysis and records the pressures, is simple to use.”

In addition to indicating the status of a malaria infection, RBC deformability information would be valuable in the development of antimalarial drugs, as well as in illuminating the mechanism by which RBCs are sequestered from circulation and destroyed.

Healthy RBCs are extremely flexible, capable of squeezing through spaces — the tiniest blood vessels, for example, or the channels between cells — that are just fractions of their original size. By rendering them less deformable, malaria parasites impair blood flow and ultimately cause organ failure and possibly death.

According to the World Health Organization, malaria killed an estimated 429,000 people and caused approximately 212 million clinical episodes in 2015. It primarily affects children and pregnant women in poor tropical and subtropical countries.

AYUSH Medicines Developed for Mosquito-Borne Diseases like Dengue

The Research Councils viz Central Council for Research in Ayurvedic Science (CCRAS), Central Council for Research in Unani Medicine (CCRUM), Central Council for Research in Siddha (CCRS), Central Council for Research in Homeopathy (CCRH), autonomous bodies under the Ministry of AYUSH are engaged in Research and Development of new drugs. The details of new drugs developed by the Research Councils after clinical trials are as under: –

CCRAS:-

· AYUSH Rasayan A & B for geriatric health
· AYUSH A for Bronchial Asthma

· AYUSH-D for Diabetes Mellitus

· C1 oil for wound healing

· AYUSH-SL for Lymphatic Filariasis

· PJ-7 for dengue

· Carctol-S for Ovarian Cancer

· AYUSH M-3 for Migrain

CCRH:-

· Coleus forskohlii

· Catheranthus roseus

· Buxus sempervirens

· Cynara scolymus

· Hygrophilla spinosa

· Persea Americana

CCRS:-
· D5 chooranam for Diabetes mellitus,

· Rasagandhi mezhugu for Fibroid uterus,

· Sirupeelaiyathi Kudineer in Kalladaippu (Urolithiasis)

CCRUM:-

· Z. N. 5:- A herbal composition against bronchial asthma and process for preparation thereof.

· Cap. Habis:- A herbal composition effective against nazfuddam and a process for the preparation thereof.

· Cap. Mubarak:- A novel herbal composition effective as anti pyretic and to a process for the preparation thereof.

· Cap. Nazla:- A novel herbal composition effective against coryza and a process for preparing thereof.

· Qurs. Mafasil:- A novel herbal composition (sugar coated) effective against rheumatoid arthritis.

· Cap. Hudar:- A herbal composition effective against arthritis and to process for the preparation thereof.

· Qurs. Mulaiyin:- A novel herbal composition and a process for preparation thereof effective against constipation.

· Cap. Deedan:- A Novel Herbal Composition And A Process For Preparation Thereof Effective Against Abdominal Worm.

This information was given by the Minister of State (Independent Charge) for AYUSH, Shri ShripadYesso Naik in written reply to a question in Rajya Sabha today.

Clinical Trials of Antibiotics on Children

Central Licensing Authority i.e. Drugs Controller General (India) has given approval for conduct of various clinical trials of Antibiotics on children under one year of age. During the last three years, such clinical trials approved were mainly related to trials in Multi Drug Resistant Tuberculosis (MDRTB) and Tuberculosis Meningitis in children. The details of the clinical trials are registered in Clinical Trial Registry of India (CTRI), which is publicly available (www.ctri.nic.in).

Antibiotic use is a major driver of resistance. Neonates are more prone to infections and vulnerable to ineffective treatment. Sepsis remains a leading cause of mortality and morbidity, especially during the first five days of life and in low and middle-income countries (LMIC).

Antibiotics are included in Schedule H and H1 to the Drugs & Cosmetics Rules, 1945, and, therefore, cannot be sold in retail except on and in accordance with the prescription of a Registered Medical Practitioner.

Indian Council of Medical Research (ICMR) has launched a programme on Antimicrobial Stewardship, Prevention of Infection and Control (ASPIC) in 2012. Functional infection control programmes not only cut down the rates of nosocomial infections, but also reduce the volume of antibiotic consumption and are a critical part of any comprehensive strategy to contain antimicrobial resistance (AMR). Further, a red line campaign has been launched to regulate over the counter sale of Schedule H antibiotics. The campaign is aimed at discouraging unnecessary prescription and over-the-counter sale of antibiotics causing drug resistance for several critical diseases including TB, malaria, urinary tract infection and even HIV.

The Ministry of Health & Family Welfare has also launched a programme named ‘National Programme on Containment of Antimicrobial Resistance’ to address the problem of growing AMR.

The Minister of State (Health and Family Welfare), Sh Faggan Singh Kulaste stated this in a written reply in the Rajya Sabha here today.